PDS Planning Inc Sells 243 Shares of Johnson & Johnson $JNJ

PDS Planning Inc reduced its stake in Johnson & Johnson (NYSE:JNJ) by 1.3% during the second quarter, according to its most recent filing with the SEC. The fund owned 18,343 shares of the company’s stock after selling 243 shares during the quarter. PDS Planning Inc’s holdings in Johnson & Johnson were worth $2,802,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. JB Capital LLC lifted its holdings in shares of Johnson & Johnson by 4.2% in the second quarter. JB Capital LLC now owns 9,011 shares of the company’s stock worth $1,377,000 after buying an additional 360 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Johnson & Johnson by 1.6% in the second quarter. Blue Trust Inc. now owns 66,941 shares of the company’s stock worth $10,225,000 after buying an additional 1,066 shares in the last quarter. Cascade Investment Group Inc. lifted its holdings in shares of Johnson & Johnson by 56.1% in the second quarter. Cascade Investment Group Inc. now owns 4,085 shares of the company’s stock worth $624,000 after buying an additional 1,468 shares in the last quarter. Monument Capital Management lifted its holdings in shares of Johnson & Johnson by 44.3% in the second quarter. Monument Capital Management now owns 6,012 shares of the company’s stock worth $918,000 after buying an additional 1,847 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC increased its position in shares of Johnson & Johnson by 2.8% in the second quarter. Cyndeo Wealth Partners LLC now owns 63,594 shares of the company’s stock worth $9,714,000 after purchasing an additional 1,753 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on JNJ shares. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. UBS Group set a $198.00 price target on shares of Johnson & Johnson in a research report on Friday, October 3rd. Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Citigroup increased their price objective on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Finally, The Goldman Sachs Group increased their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $192.94.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ opened at $190.66 on Monday. The stock has a 50-day moving average price of $178.48 and a 200-day moving average price of $163.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market cap of $459.16 billion, a PE ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $24.02 billion during the quarter. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.